SB
RANI icon

Samsara BioCapital’s Rani Therapeutics RANI Stock Holding History

Samsara BioCapital’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.25M Hold
8,500,000
– – 0.61% 19
2025
Q4 		$11.5M Buy
+8,500,000
New +$12.8M 1.18% 13

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Samsara BioCapital's RANI Position: Q1 2026 in Review

Samsara BioCapital held its Rani Therapeutics (RANI) position steady in Q1 2026 at 8,500,000 shares worth $6.25M. The position accounts for 0.61% of the portfolio, ranked #19.

Samsara BioCapital first reported a position in RANI in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.5M in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Samsara BioCapital held 8,500,000 shares of Rani Therapeutics worth $6.25M as of Q1 2026.
  • Samsara BioCapital left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up 0.61% of Samsara BioCapital's portfolio in Q1 2026, its #19 holding.
  • Samsara BioCapital first reported a position in Rani Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Samsara BioCapital's Rani Therapeutics position peaked at $11.5M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.